Critical Insights From Apellis Pharmaceuticals Analyst Ratings: What You Need To Know
Portfolio Pulse from Benzinga Insights
Analysts have provided diverse evaluations of Apellis Pharmaceuticals (NASDAQ:APLS) over the past three months, with a mix of bullish and somewhat bullish ratings. The average 12-month price target has decreased by 7.24% to $79.69. Key financial metrics show strong revenue growth but challenges in profitability and returns.
August 02, 2024 | 12:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Analysts have mixed views on Apellis Pharmaceuticals, with a recent decrease in the average 12-month price target to $79.69. The company shows strong revenue growth but faces challenges in profitability and returns.
The mixed analyst ratings and the decrease in the average price target suggest a neutral short-term impact on the stock price. While the company shows strong revenue growth, challenges in profitability and returns may offset positive sentiments.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100